Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
Huikuan Chu, Yi Duan, Ling Yang, et al.
Gut (2018) Vol. 68, Iss. 2, pp. 359-370
Open Access | Times Cited: 304

Showing 1-25 of 304 citing articles:

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron‐Wisnewsky, Chloé Vigliotti, Julia J. Witjes, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 5, pp. 279-297
Open Access | Times Cited: 759
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
Xiang Zhang, Olabisi Oluwabukola Coker, Eagle SH Chu, et al.
Gut (2020) Vol. 70, Iss. 4, pp. 761-774
Open Access | Times Cited: 603
Role and Mechanism of Gut Microbiota in Human Disease
Yinwei Chen, Jinghua Zhou, Li Wang
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 428
Gut microbiome, liver immunology, and liver diseases
Rui Wang, Ruqi Tang, Bo Li, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 4-17
Open Access | Times Cited: 293
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Herbert Tilg, Timon E. Adolph, Alexander R. Moschen
Hepatology (2020) Vol. 73, Iss. 2, pp. 833-842
Open Access | Times Cited: 291
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Fei Chen, Saeed Esmaili, Geraint B. Rogers, et al.
Hepatology (2019) Vol. 71, Iss. 4, pp. 1213-1227
Open Access | Times Cited: 275
Lactobacillus and Bifidobacterium Improves Physiological Function and Cognitive Ability in Aged Mice by the Regulation of Gut Microbiota
Yinhua Ni, Xin Yang, Liujie Zheng, et al.
Molecular Nutrition & Food Research (2019) Vol. 63, Iss. 22
Closed Access | Times Cited: 204
Microbiome—Microbial Metabolome—Cancer Cell Interactions in Breast Cancer—Familiar, but Unexplored
Edit Mikó, Tündé Kovàcs, Éva Sebő, et al.
Cells (2019) Vol. 8, Iss. 4, pp. 293-293
Open Access | Times Cited: 177
The microbiota in cirrhosis and its role in hepatic decompensation
Jonel Trebicka, Jane Macnaughtan, Bernd Schnabl, et al.
Journal of Hepatology (2021) Vol. 75, pp. S67-S81
Open Access | Times Cited: 174
Depolymerized RG-I-enriched pectin from citrus segment membranes modulates gut microbiota, increases SCFA production, and promotes the growth ofBifidobacteriumspp.,Lactobacillusspp. andFaecalibaculumspp.
Guizhu Mao, Shan Li, Caroline Orfila, et al.
Food & Function (2019) Vol. 10, Iss. 12, pp. 7828-7843
Closed Access | Times Cited: 168
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Sonja Lang, Bernd Schnabl
Cell Host & Microbe (2020) Vol. 28, Iss. 2, pp. 233-244
Open Access | Times Cited: 168
Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options
Tomáš Hrnčíř
Microorganisms (2022) Vol. 10, Iss. 3, pp. 578-578
Open Access | Times Cited: 166
Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation
Tim Hendrikx, Bernd Schnabl
Journal of Internal Medicine (2019) Vol. 286, Iss. 1, pp. 32-40
Open Access | Times Cited: 159
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 157
Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence
Xinmei Xu, Huan Yi, Jiasi Wu, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 133, pp. 110984-110984
Open Access | Times Cited: 156
Role of the Gut–Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship
Naoko Ohtani, Norifumi Kawada
Hepatology Communications (2019) Vol. 3, Iss. 4, pp. 456-470
Open Access | Times Cited: 144
Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions
Tomáš Hrnčíř, Tomáš Hrnčíř, Miloslav Kverka, et al.
Microorganisms (2021) Vol. 9, Iss. 5, pp. 957-957
Open Access | Times Cited: 131
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
Lan-Feng Xue, Zhiliang Deng, Wen-hui Luo, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 131
Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease
Jing Cong, Ping Zhou, Ruiyan Zhang
Nutrients (2022) Vol. 14, Iss. 9, pp. 1977-1977
Open Access | Times Cited: 119
The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence
Huan Yi, Hengyang Peng, Xinyue Wu, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 118
Lycium ruthenicum Anthocyanins Attenuate High‐Fat Diet‐Induced Colonic Barrier Dysfunction and Inflammation in Mice by Modulating the Gut Microbiota
Baoming Tian, Jianhua Zhao, Min Zhang, et al.
Molecular Nutrition & Food Research (2021) Vol. 65, Iss. 8
Closed Access | Times Cited: 114
Maintaining homeostatic control of periodontal bone tissue
Jessica D. Hathaway‐Schrader, Chad M. Novince
Periodontology 2000 (2021) Vol. 86, Iss. 1, pp. 157-187
Open Access | Times Cited: 112
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Tingying Jiao, Yuandi Ma, Xiaozhen Guo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1103-1119
Open Access | Times Cited: 72
Promises of microbiome-based therapies
Jasmohan S. Bajaj, Siew C. Ng, Bernd Schnabl
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1379-1391
Open Access | Times Cited: 71
Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae
Lin Gan, Yanling Feng, Bing Du, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 54
Page 1 - Next Page

Scroll to top